- Global Pharma News & Resources

BenevolentAI strengthens its Board of Directors with the appointment of digital innovation expert Marcello Damiani

London, UK, 22 March 2023: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery and development company, today announces the appointment of Marcello Damiani to its Board of Directors. His official appointment will be confirmed by the Company’s Annual General Meeting of Shareholders, which will be held on 4 May 2023. Marcello will act as an Independent Non-Executive Director of the Company.

Dr. François Nader, Chairman of BenevolentAI, said: “We are pleased to welcome Marcello to our Board as a Non-Executive Director. Drawing from his senior executive leadership experience at global organisations such as Moderna and bioMérieux, Marcello offers a unique perspective and understanding of innovation in the technology and biotech sectors. His experience will further strengthen the existing diversity and knowledge of our Board as BenevolentAI continues to execute its ambitious growth strategy.”

Marcello Damiani, said: “Technologies such as artificial intelligence offer huge promise to unlock complex biology and uncover new medicines for a broad range of debilitating diseases. I am delighted to work alongside BenevolentAI’s Board of Directors and leadership team to deliver on this promise and, in so doing, deliver a new generation of transformative medicines to patients.”

Joanna Shields, Chief Executive Officer and Board Director of BenevolentAI, said: “BenevolentAI is, at its core, a technology development company with a mission to understand complex disease biology and enable scientists to make novel discoveries. Marcello’s expertise in driving innovation in biopharma will be an invaluable addition to our Board as we continue to scale the impact of our platform and AI tools.”

Marcello has over 25 years of experience in senior executive positions in both private and publicly listed companies in the aerospace, high-tech and biotech industries. He is the former Chief Digital and Operational Excellence Officer of Moderna Inc. (Nasdaq: MRNA), where he built the technology, processes, and digitisation landscape required to advance a new class of medicines based on mRNA science. Before joining Moderna in 2015, he served as Sr. Vice President & group CIO at bioMérieux from 2010 to 2015, having joined in 2009 as Executive Director, IT Global Infrastructure services.

Marcello holds an MBA from TRIUM, an MSc in Information Systems Architecture from the University of Toulouse, France and a BSc in Computer Science from the University of Toulouse, France. He also serves on the Board of Cellarity, a biotech company based in Cambridge, MA.

Editor Details

Related Links

Last Updated: 23-Mar-2023